Undisclosed voltage-gated neuronal calcium channel inhibitor / Lario Therapeutics - LARVOL DELTA

Lario raises $2.4m for neurological drug development (Drug Target Review) - "The $1.5 million grant from The Michael J. Fox Foundation will support the progression of Lario’s research into CaV1.3-linked Parkinson’s disease biology...In parallel, the $900,000 grant from Wellcome will fund further validation of CaV2.3 as a target in post-traumatic stress disorder. The work builds on large-scale human genetics research linking variation in the CACNA1E gene, which encodes CaV2.3, to an increased risk of the condition....The company plans to initiate IND-enabling studies in 2026, followed by an IND filing and subsequent first-in-human clinical trials."

Financing • First-in-human • IND • New trial • Parkinson's Disease